Implantica AG has expanded the availability of its innovative RefluxStop™ treatment to Hospital Universitario Central de Asturias in Oviedo, officially designating it as a new Center of Excellence in Spain. This makes it the 15th top medical center in the country to offer the novel procedure since its launch two years ago. The hospital, known as the leading healthcare provider in the Asturias region, recently performed its first RefluxStop™ procedures under the leadership of Dra. Maria Moreno Gijón.

Dra. Moreno Gijón highlighted the importance of RefluxStop™ for gastroesophageal reflux disease (GERD) patients who have not responded to medication or are ineligible for conventional surgical options. Unlike traditional treatments that encircle the esophagus, RefluxStop™ addresses GERD at its source without restricting the food passage, offering a safer and more durable solution. She expressed optimism about the technology’s potential to significantly improve patient outcomes and quality of life.

Implantica CEO Dr. Peter Forsell emphasized the rapid adoption of RefluxStop™ among leading Spanish surgeons, underscoring the unmet need in treating acid reflux. He noted that up to 40% of GERD patients do not respond to proton pump inhibitors (PPIs), and many are left without viable surgical options. With RefluxStop™, these patients now have access to a transformative therapy that restores hope and delivers relief from chronic symptoms.